Blueprint Pocfratio vs Days Sales Outstanding Analysis

BPMC Stock

USD 90.46 0.13 0.14%

Blueprint Medicines financial indicator trend analysis is way more than just evaluating Blueprint Medicines Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Blueprint Medicines Corp is a good investment. Please check the relationship between Blueprint Medicines Pocfratio and its Days Sales Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Pocfratio vs Days Sales Outstanding

Pocfratio vs Days Sales Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Blueprint Medicines Corp Pocfratio account and Days Sales Outstanding. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Blueprint Medicines' Pocfratio and Days Sales Outstanding is -0.07. Overlapping area represents the amount of variation of Pocfratio that can explain the historical movement of Days Sales Outstanding in the same time period over historical financial statements of Blueprint Medicines Corp, assuming nothing else is changed. The correlation between historical values of Blueprint Medicines' Pocfratio and Days Sales Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pocfratio of Blueprint Medicines Corp are associated (or correlated) with its Days Sales Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Days Sales Outstanding has no effect on the direction of Pocfratio i.e., Blueprint Medicines' Pocfratio and Days Sales Outstanding go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Pocfratio

Days Sales Outstanding

Most indicators from Blueprint Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At present, Blueprint Medicines' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.12, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.

	2021	2022	2023	2024 (projected)
Interest Expense	7.4M	16.8M	51.6M	54.2M
Depreciation And Amortization	12.8M	20.1M	11.7M	7.7M

Interest Expense Depreciation And Amortization

Blueprint Medicines fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.5	0.07	0.81	0.84	0.48	0.89	0.42	-0.03	-0.68	0.74	0.56	0.88	0.65	0.59	0.78	0.99	0.9	0.94	0.56	0.18	0.95	0.63	0.83	0.94	0.46
Short Long Term Debt Total	0.5		0.03	0.88	-0.03	0.99	0.59	0.36	0.78	-0.94	0.3	-0.14	0.27	0.95	-0.07	0.22	0.42	0.55	0.59	0.99	0.08	0.63	0.98	0.8	0.58	0.96
Other Current Liab	0.07	0.03		0.16	0.16	-0.07	0.11	-0.85	0.12	-0.11	0.46	0.16	0.24	0.2	0.17	0.0	0.08	0.15	0.13	-0.06	0.19	0.08	-0.01	0.16	-0.06	0.29
Total Current Liabilities	0.81	0.88	0.16		0.4	0.85	0.87	0.37	0.53	-0.97	0.67	0.13	0.64	0.97	0.2	0.59	0.75	0.83	0.88	0.9	0.25	0.9	0.94	0.98	0.82	0.85
Total Stockholder Equity	0.84	-0.03	0.16	0.4		-0.06	0.63	0.17	-0.51	-0.2	0.67	0.78	0.87	0.17	0.77	0.72	0.89	0.67	0.69	0.03	0.13	0.67	0.12	0.46	0.7	-0.02
Other Liab	0.48	0.99	-0.07	0.85	-0.06		0.54	0.44	0.75	-0.92	0.24	-0.13	0.2	0.92	-0.1	0.21	0.4	0.56	0.58	0.99	0.05	0.61	0.98	0.76	0.6	0.92
Property Plant And Equipment Net	0.89	0.59	0.11	0.87	0.63	0.54		0.41	0.23	-0.8	0.8	0.24	0.79	0.75	0.34	0.81	0.84	0.87	0.93	0.64	0.46	0.96	0.7	0.93	0.84	0.54
Current Deferred Revenue	0.42	0.36	-0.85	0.37	0.17	0.44	0.41		0.08	-0.38	0.0	-0.03	0.2	0.29	-0.01	0.41	0.39	0.33	0.39	0.47	-0.01	0.43	0.45	0.38	0.51	0.1
Net Debt	-0.03	0.78	0.12	0.53	-0.51	0.75	0.23	0.08		-0.67	0.04	-0.7	-0.11	0.7	-0.43	-0.04	-0.13	0.09	0.15	0.73	0.09	0.19	0.7	0.48	0.03	0.78
Retained Earnings	-0.68	-0.94	-0.11	-0.97	-0.2	-0.92	-0.8	-0.38	-0.67		-0.58	0.03	-0.47	-0.99	0.01	-0.49	-0.61	-0.76	-0.8	-0.95	-0.23	-0.83	-0.97	-0.94	-0.73	-0.9
Accounts Payable	0.74	0.3	0.46	0.67	0.67	0.24	0.8	0.0	0.04	-0.58		0.36	0.76	0.57	0.21	0.67	0.72	0.79	0.81	0.32	0.31	0.79	0.41	0.74	0.62	0.37
Cash	0.56	-0.14	0.16	0.13	0.78	-0.13	0.24	-0.03	-0.7	0.03	0.36		0.49	-0.04	0.65	0.21	0.64	0.46	0.39	-0.11	-0.04	0.36	-0.05	0.12	0.54	-0.09
Non Current Assets Total	0.88	0.27	0.24	0.64	0.87	0.2	0.79	0.2	-0.11	-0.47	0.76	0.49		0.45	0.7	0.71	0.89	0.68	0.75	0.3	0.1	0.78	0.39	0.71	0.67	0.3
Non Currrent Assets Other	0.65	0.95	0.2	0.97	0.17	0.92	0.75	0.29	0.7	-0.99	0.57	-0.04	0.45		0.0	0.44	0.57	0.73	0.77	0.95	0.22	0.78	0.97	0.92	0.7	0.93
Other Assets	0.59	-0.07	0.17	0.2	0.77	-0.1	0.34	-0.01	-0.43	0.01	0.21	0.65	0.7	0.0		0.41	0.65	0.31	0.34	-0.05	-0.02	0.36	0.01	0.2	0.43	-0.01
Long Term Debt	0.78	0.22	0.0	0.59	0.72	0.21	0.81	0.41	-0.04	-0.49	0.67	0.21	0.71	0.44	0.41		0.77	0.74	0.82	0.3	0.43	0.78	0.37	0.67	0.72	0.13
Cash And Short Term Investments	0.99	0.42	0.08	0.75	0.89	0.4	0.84	0.39	-0.13	-0.61	0.72	0.64	0.89	0.57	0.65	0.77		0.87	0.9	0.48	0.15	0.9	0.55	0.77	0.92	0.39
Common Stock Total Equity	0.9	0.55	0.15	0.83	0.67	0.56	0.87	0.33	0.09	-0.76	0.79	0.46	0.68	0.73	0.31	0.74	0.87		0.97	0.61	0.29	0.94	0.67	0.82	0.93	0.53
Common Stock Shares Outstanding	0.94	0.59	0.13	0.88	0.69	0.58	0.93	0.39	0.15	-0.8	0.81	0.39	0.75	0.77	0.34	0.82	0.9	0.97		0.65	0.31	0.98	0.71	0.89	0.94	0.55
Non Current Liabilities Total	0.56	0.99	-0.06	0.9	0.03	0.99	0.64	0.47	0.73	-0.95	0.32	-0.11	0.3	0.95	-0.05	0.3	0.48	0.61	0.65		0.11	0.68	0.99	0.83	0.65	0.92
Other Current Assets	0.18	0.08	0.19	0.25	0.13	0.05	0.46	-0.01	0.09	-0.23	0.31	-0.04	0.1	0.22	-0.02	0.43	0.15	0.29	0.31	0.11		0.25	0.15	0.36	0.21	0.05
Other Stockholder Equity	0.95	0.63	0.08	0.9	0.67	0.61	0.96	0.43	0.19	-0.83	0.79	0.36	0.78	0.78	0.36	0.78	0.9	0.94	0.98	0.68	0.25		0.75	0.91	0.93	0.58
Total Liab	0.63	0.98	-0.01	0.94	0.12	0.98	0.7	0.45	0.7	-0.97	0.41	-0.05	0.39	0.97	0.01	0.37	0.55	0.67	0.71	0.99	0.15	0.75		0.88	0.7	0.92
Property Plant And Equipment Gross	0.83	0.8	0.16	0.98	0.46	0.76	0.93	0.38	0.48	-0.94	0.74	0.12	0.71	0.92	0.2	0.67	0.77	0.82	0.89	0.83	0.36	0.91	0.88		0.8	0.77
Total Current Assets	0.94	0.58	-0.06	0.82	0.7	0.6	0.84	0.51	0.03	-0.73	0.62	0.54	0.67	0.7	0.43	0.72	0.92	0.93	0.94	0.65	0.21	0.93	0.7	0.8		0.51
Short Term Debt	0.46	0.96	0.29	0.85	-0.02	0.92	0.54	0.1	0.78	-0.9	0.37	-0.09	0.3	0.93	-0.01	0.13	0.39	0.53	0.55	0.92	0.05	0.58	0.92	0.77	0.51

Click cells to compare fundamentals

Blueprint Medicines Account Relationship Matchups

Blueprint Medicines fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	707.7M	1.7B	1.3B	1.3B	1.0B	784.9M
Short Long Term Debt Total	95.9M	89.6M	111.4M	562.7M	774.1M	812.8M
Other Current Liab	88.7M	98.0M	113.7M	(295.5M)	128.0M	134.4M
Total Current Liabilities	106.5M	130.8M	149.8M	183.2M	214.9M	225.7M
Total Stockholder Equity	464.4M	1.5B	970.7M	514.7M	130.6M	124.1M
Other Liab	47.7M	35.8M	28.4M	437.0M	502.5M	527.6M
Property Plant And Equipment Net	111.1M	101.7M	120.9M	115.2M	115.7M	63.4M
Current Deferred Revenue	6.2M	12.6M	36.6M	448.6M	812K	771.4K
Net Debt	(18.0M)	(595.0M)	(98.5M)	122.7M	702.8M	738.0M
Retained Earnings	(945.2M)	(631.4M)	(1.3B)	(1.8B)	(2.3B)	(2.2B)
Accounts Payable	4.8M	4.4M	8.3M	2.7M	4.7M	3.9M
Cash	113.9M	684.6M	209.9M	119.7M	71.3M	67.7M
Non Current Assets Total	190.9M	790.6M	698.2M	303.3M	240.9M	236.9M
Non Currrent Assets Other	15.4M	11.1M	19.8M	26.8M	40.9M	42.9M
Other Assets	15.4M	569.3M	19.8M	26.8M	1.0	0.95
Cash And Short Term Investments	548.0M	1.5B	1.0B	1.1B	710.6M	656.9M
Common Stock Total Equity	49K	58K	59K	60K	69K	41.4K
Common Stock Shares Outstanding	47.8M	56.2M	58.5M	59.6M	60.6M	43.6M
Liabilities And Stockholders Equity	707.7M	1.7B	1.3B	1.3B	1.0B	784.9M
Non Current Liabilities Total	136.9M	117.5M	131.7M	652.0M	703.7M	738.9M
Other Current Assets	379.4M	22.0M	18.1M	35.0M	33.4M	51.4M
Other Stockholder Equity	1.4B	2.1B	2.3B	2.4B	2.5B	1.3B
Total Liab	243.3M	248.3M	281.5M	835.2M	918.6M	964.6M
Property Plant And Equipment Gross	111.1M	101.7M	146.3M	146.5M	154.1M	161.9M
Total Current Assets	516.8M	927.8M	554.0M	1.0B	808.4M	548.0M
Accumulated Other Comprehensive Income	(2.5M)	(5.2M)	(4.1M)	(10.4M)	(3.5M)	(3.7M)
Short Term Debt	6.8M	15.9M	16.2M	27.4M	81.4M	85.5M
Common Stock	49K	58K	59K	60K	61K	43.7K
Property Plant Equipment	38.4M	34.1M	30.7M	33.3M	38.3M	22.7M
Net Tangible Assets	464.4M	1.5B	1.2B	514.7M	591.9M	613.2M
Net Receivables	23.4M	25.3M	37.0M	36.9M	43.2M	45.3M
Short Term Investments	369.6M	187.2M	267.2M	825.3M	639.4M	346.5M
Retained Earnings Total Equity	(945.2M)	(631.4M)	(1.3B)	(1.8B)	(1.6B)	(1.6B)
Capital Surpluse	1.4B	2.1B	2.3B	2.4B	2.7B	1.5B
Inventory	(434.0M)	8.6M	21.8M	29.7M	21.2M	22.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:

How To Invest In Blueprint

Details

Is Blueprint Stock a good investment?

Details

What is Blueprint Medicines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.09)

Revenue Per Share

6.986

Quarterly Revenue Growth

1.266

Return On Assets

(0.15)

Return On Equity

(0.50)

The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Blueprint Pocfratio vs Days Sales Outstanding Analysis

Pocfratio vs Days Sales Outstanding

Pocfratio vs Days Sales Outstanding Correlation Analysis

Correlation Coefficient

Pocfratio

Days Sales Outstanding

Blueprint Medicines fundamental ratios Correlations

Blueprint Medicines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Blueprint Medicines fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Total Assets
Other Liab	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Other Liab
Total Liab	+ 0.99	Non Current Liabilities Total
Total Liab	+ 0.98	Short Long Term Debt Total

Non Currrent Assets Other	- 0.99	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Non Current Liabilities Total	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Short Long Term Debt Total